ProBioGen AG, a premier German service & technology provider for complex biologics today proudly announced that their CSO, Dr. Volker Sandig was awarded the first ESACT Innovation Award during yesterday’s ESACT bi-annual scientific meeting in Copenhagen.
The ESACT Innovation Award recognizes outstanding innovators and contributors to the field of Animal Cell Culture Technology (ACCT) and honors scientific ideas and developments that lead to novel applications in the biopharmaceutical industry. Dr. Sandig presented an overview of his applied research during the Innovation Award Lecture at the ESACT Scientific Meeting. Among the presented technologies that profoundly impacted development and manufacturing in the biopharmaceutical industry are the GlymaxX® ADCC enhancement technology and the AGE1.CR® duck cell line platform to manufacture animal and human vaccines.
“We are very pleased that the scientific accomplishments of our CSO in the biologics field were honored”, said ProBioGen’s CEO, Dr. Wieland Wolf. “Volker’s achievements in cell and vector biotechnology as well as in the development of innovative vaccine technologies have significantly expedited the successful development of ProBioGen.”
About ProBioGen AG
ProBioGen is a premier, Berlin-based specialist for developing and manufacturing complex therapeutic antibodies and glycoproteins, viral vectors and vaccine technologies. Combining both state-of-the-art development services, based on ProBioGen’s CHO-RiGHTTM expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties. Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen was founded 1994, is privately owned and located in Berlin, Germany.
